Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16716199 | 0.81 | LMNA (0.36) | LMNAMEN1KMT2AEGLN2EGLN1 | |
| SCHEMBL13104068 | 0.79 | LMNA (0.38) | LMNAMEN1KMT2AFFAR2EGLN2 | |
| SCHEMBL2305852 | 0.79 | IDH1 (0.36) | LMNAMEN1KMT2AEGLN2EGLN1 | |
| SCHEMBL20907801 | 0.79 | LOXL2 (0.36) | LMNAMEN1KMT2AEGLN2EGLN1 | |
| SCHEMBL485332 | 0.79 | SCN9A (0.37) | LMNAMEN1KMT2AFFAR2EGLN2 | |
| SCHEMBL24676686 | 0.76 | TKT (0.35) | LMNAMEN1KMT2AFFAR2EGLN2 | |
| SCHEMBL13021191 | 0.76 | LMNA (0.39) | LMNAMEN1KMT2AFFAR2MCHR1 | |
| SCHEMBL19370158 | 0.76 | LOXL2 (0.46) | LMNAMEN1KMT2ASCN9A | |
| SCHEMBL28860776 | 0.76 | LMNA (0.36) | LMNAMEN1KMT2AFFAR2MCHR1 | |
| SCHEMBL6497565 | 0.75 | ALDH1A1 (0.40) | LMNAMEN1KMT2ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-16 | — | — | US | disclosed |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-16 | — | — | US | disclosed |
| EP-3609880-A1 | LIVER X RECEPTORS (LXR) MODULATORS | Phenex-FXR GmbH (DE) | 2020-02-19 | — | — | EP | disclosed |
| CN-110546144-A | Liver X Receptor (LXR) modulators | PHENEX FXR GMBH | 2019-12-06 | — | — | CN | disclosed |
| WO-2018188795-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | LMNA 2854/4885MEN1 4850/4885KMT2A 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.